Synthesis and evaluation of antiallodynic and anticonvulsant activity of novel amide and urea derivatives of valproic acid analogues

Journal of Medicinal Chemistry

Volumn 52, Issue 22, 2009, Pages 7236-7248

  Kaufmann, Dan ^a   Bialer, Meir ^a,b   Shimshoni, Jakob Avi ^a   Devor, Marshall ^b   Yagen, Boris ^a,b  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 ETHYL 3 METHYLPENTANOYL)UREA; 1 (3,3 DIMETHYLBUTANOYL)UREA; 2 BUTYL 2 ETHYLACETAMIDE; 2 ETHYL 3,3, DIMETHYLBUTANAMIDE; 2 ETHYL 4 METHYLPENTANAMIDE; 2 ETHYL N METHYLHEXANAMIDE; 2 ETHYL N,3 DIMETHYLPENTANAMIDE; 2 ISOPROPYL 3 METHYLPENTANAMIDE; 2 ISOPROPYL N METHYLPENTANAMIDE; 2 ISOPROPYL N,3 DIMETHYLBUTANAMIDE; 2,2,3,3 TETRAMETHYLCYCLOPROPANECARBOXYLIC ACID; 3 METHYL 2 PROPYLPENTANAMIDE; AMIDE; ANTICONVULSIVE AGENT; GABAPENTIN; N,3,3 TRIMETHYLBUTANAMIDE; UNCLASSIFIED DRUG; UREA DERIVATIVE; VALPROIC ACID; VALPROIC ACID DERIVATIVE;

ALLODYNIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; MALE; NERVE LIGATION; NEUROPATHIC PAIN; NONHUMAN; RAT; SPINAL NERVE; STRUCTURE ACTIVITY RELATION;

AMIDES; ANIMALS; ANTICONVULSANTS; ELECTROSHOCK; ISOMERISM; MALE; MICE; PAIN; PENTYLENETETRAZOLE; RATS; RATS, SPRAGUE-DAWLEY; SEIZURES; SPINAL NERVES; UREA; VALPROIC ACID;

EID: 70949087351     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm901229s     Document Type: Article

References (60)

1. Gilron, I.; Coderre, T. J. Emerging drugs in neuropathic pain. Expert Opin. Emerging Drugs 2007, 12, 113-126.
2. Yogeeswari, P.; Vaigunda Ragavendran, J.; Sriram, D. Neuropathic pain: strategies in drug discovery and treatment. Expert Opin. Drug Discovery 2007, 2, 169-184. (Pubitemid 47078694)
3. Finnerup, N. B.; Otto, M.; McQuay, H. J.; Jensen, T. S.; Sindrup, S. H. Algorithmfor neuropathic pain treatment: an evidence based proposal. Pain 2005, 118, 289-305. (Pubitemid 41752987)
4. Guindon, J.; Walczak, J. S.; Beaulieu, P. Recent advances in the pharmacological management of pain. Drugs 2007, 67, 2121-2133. (Pubitemid 47557090)
5. Goodyear-Smith, F.; Halliwell, J. Anticonvulsants for neuropathic pain: gaps in the evidence. Clin. J. Pain 2009, 25, 528-536.
6. McQuay, H.; Carroll, D.; Jadad, A. R.; Wiffen, P.; Moore, A. Anticonvulsant drugs for management of pain: a systematic review. Br. Med. J. 1995, 311, 1047-1052.
7. Blackburn-Munro, G.; Erichsen, H. K. Antiepileptics and the treatment of neuropathic pain: evidence from animal models. Curr. Pharm. Des. 2005, 11, 2961-2976.
8. Devor, M. Response of Nerves to Injury in Relation to Neuropathic Pain. In Wall & Melzack's Textbook of Pain, 5th ed.; Churchill Livingstone: London, 2006; pp 905-927.
9. Loscher, W. Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action. Prog. Neurobiol. 1999, 58, 31-59.
10. Loscher, W. Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy. CNS Drugs 2002, 16, 669-694. (Pubitemid 35176853)
11. Bourgeois, F. D. B. Valpric Acid: Clinical Efficacy and Use in Epilepsy, 5th ed.; Lippincott Williams & Wilkins Publishers: New York, 2002; pp 808-817.
12. Kochar, D. K.; Jain, N.; Agarwal, R. P.; Srivastava, T.; Agarwal, P.; Gupta, S. Sodium valproate in the management of painful neuropathy in type 2 diabetes: a randomized placebo controlled study. Acta Neurol. Scand. 2002, 106, 248-252.
13. Kochar, D. K.; Rawat, N.; Agrawal, R. P.; Vyas, A.; Beniwal, R.; Kochar, S. K.; Garg, P. Sodium valproate for painful diabetic neuropathy: a randomized double-blind placebo-controlled study. QJM 2004, 97, 33-38. (Pubitemid 38195700)
14. Kochar, D. K.; Garg, P.; Bumb, R. A.; Kochar, S. K.; Mehta, R. D.; Beniwal, R.; Rawat, N. Divalproex sodium in the management of post-herpetic neuralgia: a randomized double-blind placebo-controlled study. QJM 2005, 98, 29-34.
15. Otto, M.; Bach, F. W.; Jensen, T. S.; Sindrup, S. H. Valproic acid has no effect on pain in polyneuropathy: a randomized, controlled trial. Neurology 2004, 62, 285-288.
16. Perucca, E. Birth defects after prenatal exposure to antiepileptic drugs. Lancet Neurol. 2005, 4, 781-786. (Pubitemid 41457294)
17. Koenig, S. A.; Buesing, D.; Longin, E.; Oehring, R.; Haussermann, P.; Kluger, G.; Lindmayer, F.; Hanusch, R.; Degen, I.; Kuhn, H.; Samii, K.; Jungck, A.; Bruckner, R.; Seitz, R.; Boxtermann, W.; Weber, Y.; Knapp, R.; Richard, H. H.; Weidner, B.; Kasper, J. M.; Haensch, C. A.; Fitzek, S.; Hartmann, M.; Borusiak, P.; Muller-Deile, A.; Degenhardt, V.; Korenke, G. C.; Hoppen, T.; Specht, U.; Gerstner, T. Valproic acid-induced hepatopathy: nine new fatalities in Germany from 1994 to 2003. Epilepsia 2006, 47, 2027-2031.
18. Kaneko, S.; Otani, K.; Kondo, T.; Fukushima, Y.; Kan, R.; Takeda, A.; Nakane, Y. Teratogenicity of antiepileptic drugs and drug specific malformations. Jpn. J. Psychiatry Neurol. 1993, 47, 306-308.
19. Gerstner, T.; Buesing, D.; Longin, E.; Bendl, C.; Wenzel, D.; Scheid, B.; Goetze, G.; Macke, A.; Lippert, G.; Klostermann, W.; Mayer, G.; Augspach-Hofmann, R.; Fitzek, S.; Haensch, C. A.; Reuland, M.; Koenig, S. A. Valproic acid induced encephalopathy: 19 new cases in Germany from 1994 to 2003 - a side effect associated to VPA-therapy not only in young children. Seizure 2006, 15, 443-448.
20. Rettie, A. E.; Rettenmeier, A. W.; Howald, W. N.; Baillie, T. A. Cytochrome P-450: catalyzed formation of delta 4-VPA, a toxic metabolite of valproic acid. Science 1987, 235, 890-893.
21. Rettie, A. E.; Rettenmeier, A. W.; Beyer, B. K.; Baillie, T. A.; Juchau, M. R. Valproate hydroxylation by human fetal tissues and embryotoxicity of metabolites. Clin. Pharmacol. Ther. 1986, 40, 172-177.
22. Sussman, N. M.; McLain, L. W., Jr. A direct hepatotoxic effect of valproic acid. JAMA, J. Am. Med. Assoc. 1979, 242, 1173-1174. (Pubitemid 10229556)
23. Zimmerman, H. J.; Ishak, K. G. Valproate-induced hepatic injury: analyses of 23 fatal cases. Hepatology 1982, 2, 591-597.
24. Nau, H.; Hauck, R. S.; Ehlers, K. Valproic acid-induced neural tube defects in mouse and human: aspects of chirality, alternative drug development, pharmacokinetics and possible mechanisms. Pharmacol. Toxicol. 1991, 69, 310-321.
25. Hadad, S.; Bialer, M. Pharmacokinetic analysis and antiepileptic activity of N-valproyl derivatives of GABA and glycine. Pharm. Res. 1995, 12, 905-910.
26. Hadad, S.; Bialer, M. Pharmacokinetic analysis and antiepileptic activity of two new isomers of N-valproyl glycinamide. Biopharm. Drug Dispos. 1997, 18, 557-566.
27. Haj-Yehia, A.; Bialer, M. Structure-pharmacokinetic relationships in a series of valpromide derivatives with antiepileptic activity. Pharm. Res. 1989, 6, 683-689.
28. Haj-Yehia, A.; Bialer, M. Structure-pharmacokinetic relationships in a series of short fatty acid amides that possess anticonvulsant activity. J. Pharm. Sci. 1990, 79, 719-724.
29. Isoherranen, N.; Woodhead, J. H.; White, H. S.; Bialer, M. Anticonvulsant profile of valrocemide (TV1901): a new antiepileptic drug. Epilepsia 2001, 42, 831-836. (Pubitemid 32783089)
30. Isoherranen, N.; White, H. S.; Finnell, R. H.; Yagen, B.; Woodhead, J. H.; Bennett, G. D.; Wilcox, K. S.; Barton, M. E.; Bialer, M. Anticonvulsant profile and teratogenicity of N-methyl-tetramethylcyclopropyl carboxamide: a new antiepileptic drug. Epilepsia 2002, 43, 115-126. (Pubitemid 34225991)
31. Isoherranen, N.; White, H. S.; Klein, B. D.; Roeder, M.; Woodhead, J. H.; Schurig, V.; Yagen, B.; Bialer, M. Pharmacokineticpharmacodynamic relationships of (2S,3S)-valnoctamide and its stereoisomer (2R,3S)-valnoctamide in rodent models of epilepsy. Pharm. Res. 2003, 20, 1293-1301.
32. Isoherranen, N.; Yagen, B.; Spiegelstein, O.; Finnell, R. H.; Merriweather, M.; Woodhead, J. H.; Wlodarczyk, B.; White, H. S.; Bialer, M. Anticonvulsant activity, teratogenicity and pharmacokinetics of novel valproyltaurinamide derivatives in mice. Br. J. Pharmacol. 2003, 139, 755-764.
33. Levi, M.; Yagen, B.; Bialer, M. Pharmacokinetics and antiepileptic activity of valproyl hydroxamic acid derivatives. Pharm. Res. 1997, 14, 213-217.
34. Shimshoni, J. A.; Bialer, M.; Wlodarczyk, B.; Finnell, R. H.; Yagen, B. Potent anticonvulsant urea derivatives of constitutional isomers of valproic acid. J. Med. Chem. 2007, 50, 6419-6427.
35. Sobol, E.; Yagen, B.; Winkler, I.; Britzi, M.; Gibson, D.; Bialer, M. Pharmacokinetics and metabolism of a new potent antiepileptic drug, 2,2,3,3-tetramethycyclopropanecarbonylurea, in rats. Drug Metab. Dispos. 2005, 33, 1538-1546.
36. Sobol, E.; Yagen, B.; Steve White, H.; Wilcox, K. S.; Lamb, J. G.; Pappo, O.; Wlodarczyk, B. J.; Finnell, R. H.; Bialer, M. Preclinical evaluation of 2,2,3,3-tetramethylcyclopropanecarbonylurea, a novel, second generation to valproic acid, antiepileptic drug. Neuropharmacology 2006, 51, 933-946.
37. Spiegelstein, O.; Yagen, B.; Levy, R. H.; Finnell, R. H.; Bennett, G. D.; Roeder, M.; Schurig, V.; Bialer, M. Stereoselective pharmacokinetics and pharmacodynamics of propylisopropyl acetamide, a CNS-active chiral amide analog of valproic acid. Pharm. Res. 1999, 16, 1582-1588.
38. Spiegelstein, O.; Yagen, B.; Bialer, M. Structure-pharmacokinetic- pharmacodynamic relationships of N-alkyl derivatives of the new antiepileptic drug valproyl glycinamide. Epilepsia 1999, 40, 545-552. (Pubitemid 29207317)
39. Bojic, U.; Elmazar, M. M.; Hauck, R. S.; Nau, H. Further branching of valproate-related carboxylic acids reduces the teratogenic activity, but not the anticonvulsant effect. Chem. Res. Toxicol. 1996, 9, 866-870.
40. Elmazar, M. M.; Hauck, R. S.; Nau, H. Anticonvulsant and neurotoxic activities of twelve analogues of valproic acid. J. Pharm. Sci. 1993, 82, 1255-1258.
41. Winkler, I.; Blotnik, S.; Shimshoni, J.; Yagen, B.; Devor, M.; Bialer, M. Efficacy of antiepileptic isomers of valproic acid and valpromide in a rat model of neuropathic pain. Br. J. Pharmacol. 2005, 146, 198-208.
42. Kaufmann, D.; Yagen, B.; Minert, A.; Tal, M.; Devor, M.; Bialer, M. Evaluation of the enantioselective antiallodynic and pharmacokinetic profile of propylisopropylacetamide, a chiral isomer of valproic acid amide. Neuropharmacology 2008, 54, 699-707.
43. Pfeffer, P.; Silbert, L. S.; Chirinko, J. M. Alpha anions of carboxylic acids. II. The formation and alkylationof alpha metalated aliphatic acids. J. Org. Chem 1972, 37, 451-458.
44. Sobol, E.; Bialer, M.; Yagen, B. Tetramethylcyclopropyl analogue of a leading antiepileptic drug, valproic acid. Synthesis and evaluation of anticonvulsant activity of its amide derivatives. J. Med. Chem. 2004, 47, 4316-4326.
45. Kim, S. H.; Chung, J. M. An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain 1992, 50, 355-363.
46. Chiechio, S.; Zammataro, M.; Caraci, F.; Rampello, L.; Copani, A.; Sabato, A. F.; Nicoletti, F. Pregabalin in the treatment of chronic pain: an overview. Clin. Drug Invest. 2009, 29, 203-213.
47. Berger, A.; Dukes, E. M.; Oster, G. Clinical characteristics and economic costs of patients with painful neuropathic disorders. J. Pain 2004, 5, 143-149. (Pubitemid 38879392)
48. Gilron, I.; Watson, C. P.; Cahill, C. M.; Moulin, D. E. Neuropathic pain: a practical guide for the clinician. Can. Med. Assoc. J. 2006, 175, 265-275.
49. Winkler, I.; Sobol, E.; Yagen, B.; Steinman, A.; Devor, M.; Bialer, M. Efficacy of antiepileptic tetramethylcyclopropyl analogues of valproic acid amides in a rat model of neuropathic pain. Neuropharmacology 2005, 49, 1110-1120. (Pubitemid 41608635)
50. Backonja, M.; Beydoun, A.; Edwards, K. R.; Schwartz, S. L.; Fonseca, V.; Hes, M.; LaMoreaux, L.; Garofalo, E. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA, J. Am. Med. Assoc. 1998, 280, 1831-1836. (Pubitemid 28544423)
51. Clivatti, J.; Sakata, R. K.; Issy, A. M. Review of the use of gabapentin in the control of postoperative pain. Rev. Bras. Anestesiol. 2009, 59, 87-92.
52. Segal, A. Z.; Rordorf, G. Gabapentin as a novel treatment for postherpetic neuralgia. Neurology 1996, 46, 1175-1176. (Pubitemid 26134680)
53. Abbott, F. S.; Acheampong, A. A. Quantitative structure - anticonvulsant activity relationships of valproic acid, related carboxylic acids and tetrazoles. Neuropharmacology 1988, 27, 287-294.
54. Palaty, J.; Abbott, F. S. Structure-activity relationships of unsaturated analogues of valproic acid. J. Med. Chem. 1995, 38, 3398-3406.
55. Spiegelstein, O.; Yagen, B.; Bennett, G. D.; Finnell, R. H.; Blotnik, S.; Bialer, M. Stereoselective pharmacokinetic analysis of valnoctamide, a CNS-active chiral amide analogue of valproic acid, in dogs, rats, and mice. Ther. Drug Monit. 2000, 22, 574-581.
56. Loscher, W.; Nau, H. Pharmacological evaluation of various metabolites and analogues of valproic acid. Anticonvulsant and toxic potencies in mice. Neuropharmacology 1985, 24, 427-435.
57. Green, A. R. 5-HT mediated behaviour. Neuropharmacology 2001, 23, 1521-1528.
58. Shimshoni, J. A.; Yagen, B.; Pessah, N.; Wlodarczyk, B.; Finnell, R. H.; Bialer, M. Anticonvulsant profile and teratogenicity of 3,3- dimethylbutanoylurea: a potential for a second generation drug to valproic acid. Epilepsia 2008, 49, 1202-1212. (Pubitemid 351991399)
59. Furniss, B. S.; Hannaford, A. J.; Smith, P. W. G.; Tatchell, A. R. Vogel's Textbook of Practical Organic Chemistry; Prentice Hall: New York, 1989; pp 720-723.
60. White, H. S.; Woodhead, J. H.; Wilcox, K. S.; Stables, J. P.; Kupferberg, H. J.; Wolf, W. W. Discovery and Preclinical Development of Antiepilpeitc Drugs, 5th ed.; Lippincott Williams & Wilkins Publishers: New York, 2002; pp 36-48.